Download PDF
Exp Clin Endocrinol Diabetes 2022; 130(04): 248-253
DOI: 10.1055/a-1474-8220
Review

Increased Serum WISP1 Levels are Associated with Lower Extremity Atherosclerotic Disease in Patients with Type 2 Diabetes Mellitus

Yangyang Cheng
Department of Endocrinology, Central Theater Command General Hospital of the Chinese People’s Liberation Army, Wuhan, 430070, Hubei, China
,
Xiaohui Du
Department of Endocrinology, Central Theater Command General Hospital of the Chinese People’s Liberation Army, Wuhan, 430070, Hubei, China
,
Bilin Zhang
Department of Endocrinology, Central Theater Command General Hospital of the Chinese People’s Liberation Army, Wuhan, 430070, Hubei, China
,
Junxia Zhang
Department of Endocrinology, Central Theater Command General Hospital of the Chinese People’s Liberation Army, Wuhan, 430070, Hubei, China
› Author Affiliations Funding: This work was supported with the financial support of the Bethune-Merck Diabetes Research Foundation (NO. G2018030), Natural Science Foundation of Hubei Province (Number 2020CFB574) and China Diabetes Young Scientific Talent Research Project (Number 2020-N-01).
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background Serum wnt1-induced signaling pathway protein 1 (WISP1) levels are increased with obesity, which is a common complication associated with lower extremity atherosclerotic disease (LEAD). However, to date, the relationship between elevated WISP1 levels and the incidence of lower extremity atherosclerotic disease (LEAD) in type 2 diabetes mellitus (T2DM) remains unclear.

Methods 174 newly diagnosed type 2 diabetic patients were enrolled in our study. Patients were divided into two groups, LEAD group (n=100) and control group (n=74). Anthropometric parameters, blood pressure and some biochemical parameters were obtained. Body composition was detected by bioelectrical impedance analysis (BIA). Levels of serum insulin were determined by radioimmunoassay. Serum WISP1 and interleukin 6 (IL-6) levels were determined using an enzyme-linked immunosorbent assay.

Results It was shown that serum WISP1 levels in diabetic patients with LEAD were higher than those without LEAD (P<0.001). Serum WISP1 levels were positively related with waist circumference (r=0.237, P=0.003), waist-hip ratio (r=0.22, P=0.006), visceral fat area (r=0.354, P<0.001), serum creatinine (r=0.192, P=0.012), interleukin 6 (r=0.182, P=0.032), c-reactive protein (r=0.681, P<0.001), triglycerides (r=0.119, P<0.001), fasting glucose (r=0.196, P=0.011), glycated hemoglobin (r=0.284, P<0.001), and HOMA-IR (r=0.285, P<0.026). Compared with the lowest tertile, the odds ratio of the middle tertile for LEAD incidence was 3.27 (95% CI, 1.24–8.64) and 4.46 (95% CI, 1.62–12.29) for the highest tertile after adjusting confounding factors.

Conclusion The results suggest that increased serum WISP1 levels independently contribute to the incidence of LEAD in patients with newly diagnosed T2DM.

Key words

Wnt1-induced signaling pathway protein 1 - lower extremity atherosclerotic disease - type 2 diabetes mellitus - obesity - inflammation - insulin resistance


Publication History

Received: 10 January 2021
Received: 17 March 2021

Accepted: 26 March 2021

Article published online:
30 April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Kamil S, Sehested TSG, Carlson N. et al. Diabetes and risk of peripheral artery disease in patients undergoing first-time coronary angiography between 2000 and 2012 – a nationwide study. Bmc Cardiovasc Disor 2019; 19: 234
    CrossrefPubMedSearch in Google Scholar
  • 2 Mukherjee D. Peripheral and cerebrovascular atherosclerotic disease in diabetes mellitus. Best Pract Res Cl En 2009; 23: 335-345
    CrossrefPubMedSearch in Google Scholar
  • 3 Beckman JA, Creager MA. Libby P. Diabetes and Atherosclerosis. Jama 2002; 287: 2570
    CrossrefPubMedSearch in Google Scholar
  • 4 Laclaustra M, Casasnovas JA, Fernández-Ortiz A. et al. Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium. J Am Coll Cardiol 2016; 67: 1263-1274
    CrossrefPubMedSearch in Google Scholar
  • 5 Yamada K, Yasunaga H, Kadono Y. et al. Postoperative outcomes of major lower extremity amputations in patients with diabetes and peripheral artery disease: Analysis using the Diagnosis Procedure Combination database in Japan. Am J Surg 2016; 212: 446-450
    CrossrefPubMedSearch in Google Scholar
  • 6 Collaboration ABI, Fowkes FGR, Murray GD. et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. Jama 2008; 300: 197-208
    CrossrefPubMedSearch in Google Scholar
  • 7 Vrsalovic M, Vucur K, Presecki AV. et al. Impact of diabetes on mortality in peripheral artery disease: A meta-analysis: Diabetes and mortality in peripheral artery disease: A meta-analysis. Clin Cardiol 2016; 40: 287-291
    CrossrefPubMedSearch in Google Scholar
  • 8 Berschneider B, Königshoff M. WNT1 inducible signaling pathway protein 1 (WISP1): A novel mediator linking development and disease. Int J Biochem Cell Biol 2011; 43: 306-309
    CrossrefPubMedSearch in Google Scholar
  • 9 Deng W, Fernandez A, McLaughlin SL. et al. WNT1-inducible signaling pathway protein 1 (WISP1/CCN4) stimulates melanoma invasion and metastasis by promoting the epithelial–mesenchymal transition. J Biol Chem 2019; 294: 5261-5280
    CrossrefPubMedSearch in Google Scholar
  • 10 Venkatachalam K, Venkatesan B, Valente AJ. et al. WISP1, a pro-mitogenic, pro-survival factor, mediates tumor necrosis factor-alpha (TNF-alpha)-stimulated cardiac fibroblast proliferation but inhibits TNF-alpha-induced cardiomyocyte death. J Biol Chem 2009; 284: 14414-14427
    CrossrefPubMedSearch in Google Scholar
  • 11 Murahovschi V, Pivovarova O, Ilkavets I. et al. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes 2015; 64: 856-866
    CrossrefPubMedSearch in Google Scholar
  • 12 Hörbelt T, Tacke C, Markova M. et al. The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia 2018; 61: 2054-2065
    CrossrefPubMedSearch in Google Scholar
  • 13 Klimontov VV, Bulumbaeva DM, Fazullina ON. et al. Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes. J Cell Commun Signal 2019; 1-9
    CrossrefPubMedSearch in Google Scholar
  • 14 Bedel A, Nègre-Salvayre A, Heeneman S. et al. E-cadherin/beta-catenin/T-cell factor pathway is involved in smooth muscle cell proliferation elicited by oxidized low-density lipoprotein. Circ Res 2008; 103: 694-701
    CrossrefPubMedSearch in Google Scholar
  • 15 Gu L, Chen N, Li Z. et al. Relationship of serum Wnt1-inducible signaling pathway protein 1 levels with coronary artery disease and its severity. Coronary Artery Disease 2019; 1
    CrossrefPubMedSearch in Google Scholar
  • 16 Aboyans V, Ricco J-B, Bartelink M-LEL. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2017; 39: 763-816
    CrossrefPubMedSearch in Google Scholar
  • 17 Tacke C, Aleksandrova K, Rehfeldt M. et al. Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP-1)/CCN4 as a novel biomarker of obesity. J Cell Commun Signal 2018; 12: 539-548
    CrossrefPubMedSearch in Google Scholar
  • 18 Roever LS, Resende ES, Diniz ALD. et al. Abdominal obesity and association with atherosclerosis risk factors: The Uberlândia Heart Study. Medicine 2016; 95: e1357
    CrossrefPubMedSearch in Google Scholar
  • 19 Barchetta I, Cimini FA, Capoccia D. et al. WISP1 is a marker of systemic and adipose tissue inflammation in dysmetabolic subjects with or without type 2 diabetes. J Endocr Soc 2017; 1: 660-670
    CrossrefPubMedSearch in Google Scholar
  • 20 Geovanini GR, Libby P. Atherosclerosis and inflammation: Overview and updates. Clin Sci 2018; 132: 1243-1252
    CrossrefPubMedSearch in Google Scholar
  • 21 Pino AD, DeFronzo RA. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr Rev 2019; 40: 1447-1467
    CrossrefPubMedSearch in Google Scholar
  • 22 Ersoy G, Ensari T, Subas S. et al. WISP1 is a novel adipokine linked to metabolic parameters in gestational diabetes mellitus. J Matern Fetal Neonatal Med 2016; 30: 1-5
    CrossrefPubMedSearch in Google Scholar
  • 23 Ersoy GS, Ensari TA, Vatansever D. et al. Novel adipokines WISP1 and betatrophin in PCOS: relationship to AMH levels, atherogenic and metabolic profile. Gynecol Endocrinol 2016; 33: 1-5
    CrossrefPubMedSearch in Google Scholar
  • 24 Borrell-Pagès M, Romero JC, Badimon L. LRP5 deficiency down-regulates Wnt signalling and promotes aortic lipid infiltration in hypercholesterolaemic mice. J Cell Mol Med 2015; 19: 770-777
    CrossrefPubMedSearch in Google Scholar
  • 25 Jung TW, Kang C, Goh J. et al. WISP1 promotes non-alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling. J Cell Physiol 2018; 233: 6077-6087
    CrossrefPubMedSearch in Google Scholar
  • 26 Colston JT, Rosa de la SD, Koehler M. et al. Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor. Am J Physiol-heart C 2007; 293: H1839-H1846
    CrossrefPubMedSearch in Google Scholar
  • 27 Chistiakov DA, Sobenin IA, Orekhov AN. Vascular extracellular matrix in atherosclerosis. Cardiol Rev 2013; 21: 270-288
    CrossrefPubMedSearch in Google Scholar
  • 28 Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol 2010; 10: 712-723
    CrossrefPubMedSearch in Google Scholar
  • 29 Ahmad K, Lee EJ, Moon JS. et al. Multifaceted interweaving between extracellular matrix, insulin resistance, and skeletal muscle. Cells 2018; 7: 148
    CrossrefPubMedSearch in Google Scholar
  • 30 Sala LL, Prattichizzo F, Ceriello A. The link between diabetes and atherosclerosis. Eur J Prev Cardiol 2019; 26: 15-24
    CrossrefPubMedSearch in Google Scholar
  • 31 PLSM Gordts, Esko JD. The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis. Matrix Biol 2018; 71–72: 262-282
    CrossrefPubMedSearch in Google Scholar
  • 32 Wang A, Yan X, Zhang C. et al. Characterization of Wnt1-inducible signaling pathway protein-1 in obese children and adolescents. Curr Medical Sci 2018; 38: 868-874
    CrossrefPubMedSearch in Google Scholar
  • 33 Habib NS, EL-Hefnawy MH, El-Mesallamy HO. Assessment of circulating Wnt1-inducible signaling pathway protein 1 (WISP1) in obesity and type 2 diabetes mellitus patients. Archives of Pharmaceutical Sciences Ain Shams University 2018; 2: 47-53
    CrossrefPubMedSearch in Google Scholar